These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 30375647)

  • 1. Opportunities and Challenges Related to the Implementation of Model-Based Bioequivalence Criteria.
    Seng Yue C; Ozdin D; Selber-Hnatiw S; Ducharme MP
    Clin Pharmacol Ther; 2019 Feb; 105(2):350-362. PubMed ID: 30375647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current regulatory approaches of bioequivalence testing.
    Karalis V; Macheras P
    Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):929-42. PubMed ID: 22681436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Some thoughts on drug interchangeability.
    Chow SC; Song F; Chen M
    J Biopharm Stat; 2016; 26(1):178-86. PubMed ID: 26366703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On safety margin for drug interchangeability.
    Zheng J; Chow SC; Song F
    J Biopharm Stat; 2017; 27(2):293-307. PubMed ID: 27911675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International Guidelines for Bioequivalence of Locally Acting Orally Inhaled Drug Products: Similarities and Differences.
    Lu D; Lee SL; Lionberger RA; Choi S; Adams W; Caramenico HN; Chowdhury BA; Conner DP; Katial R; Limb S; Peters JR; Yu L; Seymour S; Li BV
    AAPS J; 2015 May; 17(3):546-57. PubMed ID: 25758352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency estimator for assessing of follow-on biologics.
    Lu Y; Zhang ZZ; Chow SC
    J Biopharm Stat; 2014; 24(6):1280-97. PubMed ID: 25072640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of Different Populations on Pharmacokinetic Bioequivalence Results: Can We Extrapolate Bioequivalence Results from One Population to Another?
    Ozdin D; Ducharme MP; Varin F; Fuglsang A; Al-Numani D
    J Pharm Pharm Sci; 2020; 23():. PubMed ID: 33064978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioequivalence and other unresolved issues in generic drug substitution.
    Meredith P
    Clin Ther; 2003 Nov; 25(11):2875-90. PubMed ID: 14693311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Japanese guidance on bioavailability and bioequivalence.
    Aoyagi N
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):28-31. PubMed ID: 11032086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approximate confidence limit for the reference scaled bioequivalence with a parallel design.
    Liao JJZ; Li Y
    J Biopharm Stat; 2020 Mar; 30(2):231-243. PubMed ID: 31455199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Generic drugs in Brazil: historical overview and legislation].
    Araújo LU; Albuquerque KT; Kato KC; Silveira GS; Maciel NR; Spósito PÁ; Barcellos NM; Souza Jd; Bueno M; Storpirtis S
    Rev Panam Salud Publica; 2010 Dec; 28(6):480-92. PubMed ID: 21308175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioequivalence review for drug interchangeability.
    Chow SC; Shao J
    J Biopharm Stat; 1999 Aug; 9(3):485-97. PubMed ID: 10473033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?
    Warren JB
    Br J Clin Pharmacol; 2013 Jan; 75(1):7-14. PubMed ID: 22574725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Main concepts on bioequivalence and biosimilarity in the Chilean legislation, and current controversies on drug interchangeability.
    Stojanova J; Lutz M; Lazcano G; Arancibia M
    Medwave; 2020 Feb; 20(2):e7825. PubMed ID: 32119654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioequivalence: the regulatory career of a pharmaceutical concept.
    Carpenter D; Tobbell DA
    Bull Hist Med; 2011; 85(1):93-131. PubMed ID: 21551918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing bioequivalence and drug interchangeability.
    Chen M; Chow SC
    J Biopharm Stat; 2017; 27(2):272-281. PubMed ID: 27936343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variability and impact on design of bioequivalence studies.
    Van Peer A
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioequivalence study designs for generic solid oral anticancer drug products: scientific and regulatory considerations.
    Kaur P; Chaurasia CS; Davit BM; Conner DP
    J Clin Pharmacol; 2013 Dec; 53(12):1252-60. PubMed ID: 23996908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. United States Food and Drug Administration requirements for approval of generic drug products.
    Meyer MC
    J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generics Substitution, Bioequivalence Standards, and International Oversight: Complex Issues Facing the FDA.
    Bate R; Mathur A; Lever HM; Thakur D; Graedon J; Cooperman T; Mason P; Fox ER
    Trends Pharmacol Sci; 2016 Mar; 37(3):184-191. PubMed ID: 26687297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.